Toggle navigation
Works
People
Organizations
Repositories
Pages
About
Statistics
Support
Sign In
Loading...
Loading...
Data for: A randomized, double-blind, placebo-controlled phase 1b/2 study of ralimetinib, a p38 MAPK inhibitor, plus gemcitabine and carboplatin versus gemcitabine and carboplatin for women with recurrent platinum-sensitive ovarian cancer
https://doi.org/10.17632/yj4byrkjmj.1
Loading...
Download Metadata
Cite as
APA
Harvard
MLA
Vancouver
Chicago
IEEE
Download Reports
Related Works (CSV)
Share
Email
Twitter
Facebook
Description
Creators
Registration
Protocol and SAP
Ignace Vergote
DOI registered
March 31, 2020
via DataCite
Dataset published 2020 in
Mendeley Data
Dataset